# Propanc Biopharma, Inc.: financial statements, quarterly

PPCB · Nasdaq · CIK 1517681 · [Healthcare](/sectors/healthcare.md) · fiscal year ends Jun 30

Pages: [Overview](/companies/ppcb.md) · [Financials](/companies/ppcb/financials.md) · [Filings](/companies/ppcb/filings.md) · [Insiders](/companies/ppcb/insiders.md)

Standardized line items from XBRL company facts. Each value links to its filing; d marks a value derived from year-to-date figures. Other view: [annual](/companies/ppcb/financials.md?period=annual).

## Income statement

| Line item | Unit | Q1 FY2024 (2023-09-30) | Q2 FY2024 (2023-12-31) | Q3 FY2024 (2024-03-31) | Q4 FY2024 (2024-06-30) | Q1 FY2025 (2024-09-30) | Q2 FY2025 (2024-12-31) | Q3 FY2025 (2025-03-31) | Q4 FY2025 (2025-06-30) | Q1 FY2026 (2025-09-30) | Q2 FY2026 (2025-12-31) | Q3 FY2026 (2026-03-31) | Q4 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Cost of revenue | $m | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |
| Research and development | $m | [0.0](/filings/0001493152-24-045664.md) | [0.1](/filings/0001493152-25-006697.md) | [0.1](/filings/0001641172-25-010798.md) | [0.1 d](/filings/0001493152-25-016069.md) | [0.1](/filings/0001493152-25-023213.md) | [0.1](/filings/0001493152-26-007052.md) | [0.1](/filings/0001493152-26-023210.md) | [0.1 d](/filings/0001493152-26-044373.md) | [0.1](/filings/0001493152-25-023213.md) | [0.0](/filings/0001493152-26-007052.md) | [0.2](/filings/0001493152-26-023210.md) | [0.4 d](/filings/0001493152-26-044373.md) |
| Operating income | $m | [(0.4)](/filings/0001493152-24-045664.md) | [(0.4)](/filings/0001493152-25-006697.md) | [(0.4)](/filings/0001641172-25-010798.md) | [(0.3) d](/filings/0001493152-25-016069.md) | [(0.3)](/filings/0001493152-25-023213.md) | [(0.2)](/filings/0001493152-26-007052.md) | [(53.1)](/filings/0001493152-26-023210.md) | [(3.6) d](/filings/0001493152-26-044373.md) | [(4.7)](/filings/0001493152-25-023213.md) | [(3.7)](/filings/0001493152-26-007052.md) | [(6.4)](/filings/0001493152-26-023210.md) | [(3.5) d](/filings/0001493152-26-044373.md) |
| Interest expense | $m | [0.2](/filings/0001493152-23-040980.md) | [0.3](/filings/0001493152-24-007191.md) | [0.1](/filings/0001493152-24-019940.md) | [0.1 d](/filings/0001493152-25-016069.md) | [0.1](/filings/0001493152-25-023213.md) | [0.1](/filings/0001493152-26-007052.md) | [0.1](/filings/0001493152-26-023210.md) | [0.3 d](/filings/0001493152-26-044373.md) | [0.3](/filings/0001493152-25-023213.md) | [0.1](/filings/0001493152-26-007052.md) | [0.0](/filings/0001493152-26-023210.md) | [0.0 d](/filings/0001493152-26-044373.md) |
| Income tax | $m | not reported | [(0.1)](/filings/0001493152-25-006697.md) | [(0.0)](/filings/0001641172-25-010798.md) | [(0.0) d](/filings/0001493152-25-016069.md) | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |
| Net income | $m | [(0.4)](/filings/0001641172-25-010798.md) | [(0.6)](/filings/0001641172-25-010798.md) | [(0.5)](/filings/0001641172-25-010798.md) | [(0.4) d](/filings/0001493152-25-016069.md) | [(0.4)](/filings/0001493152-26-023210.md) | [(0.4)](/filings/0001493152-26-023210.md) | [(54.1)](/filings/0001493152-26-023210.md) | [(4.1) d](/filings/0001493152-26-044373.md) | [(4.8)](/filings/0001493152-26-023210.md) | [(3.1)](/filings/0001493152-26-023210.md) | [(6.4)](/filings/0001493152-26-023210.md) | [(4.6) d](/filings/0001493152-26-044373.md) |
| Diluted EPS | $ per share | [(0.04)](/filings/0001493152-24-045664.md) | [(1559.55)](/filings/0001493152-25-006697.md) | [(545.79)](/filings/0001641172-25-010798.md) | not reported | [(35.97)](/filings/0001493152-25-023213.md) | [(32.23)](/filings/0001493152-26-007052.md) | [(12.50)](/filings/0001493152-26-023210.md) | not reported | [(0.39)](/filings/0001493152-25-023213.md) | [(0.30)](/filings/0001493152-26-007052.md) | [(0.28)](/filings/0001493152-26-023210.md) | not reported |
| Basic EPS | $ per share | [(0.04)](/filings/0001493152-24-045664.md) | [(1559.55)](/filings/0001493152-25-006697.md) | [(545.79)](/filings/0001641172-25-010798.md) | not reported | [(35.97)](/filings/0001493152-25-023213.md) | [(32.23)](/filings/0001493152-26-007052.md) | [(12.50)](/filings/0001493152-26-023210.md) | not reported | [(0.39)](/filings/0001493152-25-023213.md) | [(0.30)](/filings/0001493152-26-007052.md) | [(0.28)](/filings/0001493152-26-023210.md) | not reported |

- Cost of revenue: not reported
- Research and development: us-gaap:ResearchAndDevelopmentExpense
- Operating income: us-gaap:OperatingIncomeLoss
- Interest expense: us-gaap:InterestExpense, us-gaap:InterestExpenseNonoperating
- Income tax: us-gaap:IncomeTaxExpenseBenefit
- Net income: us-gaap:NetIncomeLoss
- Diluted EPS: us-gaap:EarningsPerShareDiluted
- Basic EPS: us-gaap:EarningsPerShareBasic

## Balance sheet

| Line item | Unit | Q1 FY2024 (2023-09-30) | Q2 FY2024 (2023-12-31) | Q3 FY2024 (2024-03-31) | FY2024 (2024-06-30) | Q1 FY2025 (2024-09-30) | Q2 FY2025 (2024-12-31) | Q3 FY2025 (2025-03-31) | FY2025 (2025-06-30) | Q1 FY2026 (2025-09-30) | Q2 FY2026 (2025-12-31) | Q3 FY2026 (2026-03-31) | FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Cash and equivalents | $m | [0.0](/filings/0001493152-23-040980.md) | [0.1](/filings/0001493152-24-007191.md) | [0.0](/filings/0001493152-24-019940.md) | [0.0](/filings/0001493152-25-016069.md) | [0.0](/filings/0001493152-24-045664.md) | [0.0](/filings/0001493152-25-006697.md) | [0.1](/filings/0001641172-25-010798.md) | [0.0](/filings/0001493152-26-044373.md) | [0.6](/filings/0001493152-25-023213.md) | [0.6](/filings/0001493152-26-007052.md) | [0.4](/filings/0001493152-26-023210.md) | [0.8](/filings/0001493152-26-044373.md) |
| Current assets | $m | [0.1](/filings/0001493152-23-040980.md) | [0.2](/filings/0001493152-24-007191.md) | [0.0](/filings/0001493152-24-019940.md) | [0.0](/filings/0001493152-25-016069.md) | [0.0](/filings/0001493152-24-045664.md) | [0.0](/filings/0001493152-25-006697.md) | [9.7](/filings/0001641172-25-010798.md) | [8.4](/filings/0001493152-26-044373.md) | [8.8](/filings/0001493152-25-023213.md) | [7.7](/filings/0001493152-26-007052.md) | [8.2](/filings/0001493152-26-023210.md) | [8.5](/filings/0001493152-26-044373.md) |
| Total assets | $m | [0.2](/filings/0001493152-23-040980.md) | [0.2](/filings/0001493152-24-007191.md) | [0.0](/filings/0001493152-24-019940.md) | [0.1](/filings/0001493152-25-016069.md) | [0.1](/filings/0001493152-24-045664.md) | [0.1](/filings/0001493152-25-006697.md) | [22.5](/filings/0001641172-25-010798.md) | [19.6](/filings/0001493152-26-044373.md) | [18.0](/filings/0001493152-25-023213.md) | [15.1](/filings/0001493152-26-007052.md) | [14.3](/filings/0001493152-26-023210.md) | [12.8](/filings/0001493152-26-044373.md) |
| Current liabilities | $m | [3.1](/filings/0001493152-23-040980.md) | [3.8](/filings/0001493152-24-007191.md) | [3.7](/filings/0001493152-24-019940.md) | [3.8](/filings/0001493152-25-016069.md) | [4.1](/filings/0001493152-24-045664.md) | [4.2](/filings/0001493152-25-006697.md) | [4.3](/filings/0001641172-25-010798.md) | [5.6](/filings/0001493152-26-044373.md) | [3.6](/filings/0001493152-25-023213.md) | [3.6](/filings/0001493152-26-007052.md) | [3.5](/filings/0001493152-26-023210.md) | [3.4](/filings/0001493152-26-044373.md) |
| Total liabilities | $m | [3.2](/filings/0001493152-23-040980.md) | [3.8](/filings/0001493152-24-007191.md) | [3.7](/filings/0001493152-24-019940.md) | [3.9](/filings/0001493152-25-016069.md) | [4.2](/filings/0001493152-24-045664.md) | [4.2](/filings/0001493152-25-006697.md) | [4.4](/filings/0001641172-25-010798.md) | [5.7](/filings/0001493152-26-044373.md) | [3.6](/filings/0001493152-25-023213.md) | [3.7](/filings/0001493152-26-007052.md) | [3.5](/filings/0001493152-26-023210.md) | [3.4](/filings/0001493152-26-044373.md) |
| Long-term debt | $m | [0.4](/filings/0001493152-23-040980.md) | [0.7](/filings/0001493152-24-007191.md) | [0.6](/filings/0001493152-24-019940.md) | [0.4](/filings/0001493152-25-016069.md) | [0.4](/filings/0001493152-24-045664.md) | [0.4](/filings/0001493152-25-006697.md) | [0.4](/filings/0001641172-25-010798.md) | [0.5](/filings/0001493152-26-044373.md) | [0.1](/filings/0001493152-25-023213.md) | [0.1](/filings/0001493152-26-007052.md) | [0.1](/filings/0001493152-26-023210.md) | not reported |
| Short-term borrowings | $m | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |
| Shareholders' equity | $m | [(3.0)](/filings/0001641172-25-010798.md) | [(3.6)](/filings/0001641172-25-010798.md) | [(3.7)](/filings/0001641172-25-010798.md) | [(3.8)](/filings/0001493152-26-044373.md) | [(4.1)](/filings/0001493152-26-023210.md) | [(4.2)](/filings/0001493152-26-023210.md) | [18.1](/filings/0001493152-26-023210.md) | [13.9](/filings/0001493152-26-044373.md) | [14.4](/filings/0001493152-26-023210.md) | [10.5](/filings/0001493152-26-023210.md) | [9.8](/filings/0001493152-26-023210.md) | [9.4](/filings/0001493152-26-044373.md) |

- Cash and equivalents: us-gaap:Cash
- Current assets: us-gaap:AssetsCurrent
- Total assets: us-gaap:Assets
- Current liabilities: us-gaap:LiabilitiesCurrent
- Total liabilities: us-gaap:Liabilities
- Long-term debt: us-gaap:LongTermDebt
- Short-term borrowings: not reported
- Shareholders' equity: us-gaap:StockholdersEquity

## Cash flow

| Line item | Unit | Q1 FY2024 (2023-09-30) | Q2 FY2024 (2023-12-31) | Q3 FY2024 (2024-03-31) | Q4 FY2024 (2024-06-30) | Q1 FY2025 (2024-09-30) | Q2 FY2025 (2024-12-31) | Q3 FY2025 (2025-03-31) | Q4 FY2025 (2025-06-30) | Q1 FY2026 (2025-09-30) | Q2 FY2026 (2025-12-31) | Q3 FY2026 (2026-03-31) | Q4 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Operating cash flow | $k | [(333)](/filings/0001493152-24-045664.md) | [(239) d](/filings/0001493152-25-006697.md) | [(103) d](/filings/0001641172-25-010798.md) | [(260) d](/filings/0001493152-25-016069.md) | [(236)](/filings/0001493152-25-023213.md) | [18.7 d](/filings/0001493152-26-007052.md) | [(96.2) d](/filings/0001493152-26-023210.md) | [(92.2) d](/filings/0001493152-26-044373.md) | [(1,939)](/filings/0001493152-25-023213.md) | [(999) d](/filings/0001493152-26-007052.md) | [(1,142) d](/filings/0001493152-26-023210.md) | [(1,602) d](/filings/0001493152-26-044373.md) |
| Capital expenditure | $k | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | [2.5](/filings/0001493152-25-023213.md) | [2.3 d](/filings/0001493152-26-007052.md) | [0.2 d](/filings/0001493152-26-023210.md) | [0.0 d](/filings/0001493152-26-044373.md) |

- Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities
- Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment

## Shares

| Line item | Unit | Q1 FY2023 (2022-09-30) | Q2 FY2023 (2022-12-31) | Q3 FY2023 (2023-03-31) | Q1 FY2024 (2023-09-30) | Q2 FY2024 (2023-12-31) | Q3 FY2024 (2024-03-31) | Q1 FY2025 (2024-09-30) | Q2 FY2025 (2024-12-31) | Q3 FY2025 (2025-03-31) | Q1 FY2026 (2025-09-30) | Q2 FY2026 (2025-12-31) | Q3 FY2026 (2026-03-31) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Diluted shares (weighted) | millions of shares | [0.5](/filings/0001493152-23-040980.md) | [1.0](/filings/0001493152-24-007191.md) | [1.9](/filings/0001493152-24-019940.md) | [11.0](/filings/0001493152-24-045664.md) | [0.0](/filings/0001493152-25-006697.md) | [0.0](/filings/0001641172-25-010798.md) | [0.0](/filings/0001493152-25-023213.md) | [0.0](/filings/0001493152-26-007052.md) | [4.3](/filings/0001493152-26-023210.md) | [12.3](/filings/0001493152-25-023213.md) | [13.4](/filings/0001493152-26-007052.md) | [22.4](/filings/0001493152-26-023210.md) |

- Diluted shares (weighted): us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding

Shares outstanding: 6,331,116 at 2026-09-23, from the cover of the [10-K filed 2026-09-25](/filings/0001493152-26-044373.md) (dei:EntityCommonStockSharesOutstanding).

Source: SEC EDGAR, XBRL company facts. Last ingested by Listed: Oct 24, 2026, 15:41 ET. No prices; not investment advice.